1Dygk,Adiei AA. Novel target for lung cancer therapy:part[J].Clinical Oncology,2002,(12):2881-2884.
2陈颧珠.实用内科学[M]北京:人民卫生出版社,20021593.
3Thatcher N,Chang A,Parikh P. Gdltinib plus best supportive care in previously treated patients with refractory advanced non.smau-cell lung caner:results from a randomized,p 1 acebo-controlled,multicentre study(Iressa Survival Evaluation in Lung Cancer)[J].The Lancet,2005.1527-1537.
4Shepherd FA,Rodrigues Pereim J,Ciuleanu T. Erlotinib in previously treated non-small-cell lung cancemc[J].New England Journal of Medicine,2005.123-132.
5Berthiot G,Marechalf,Cattan A. Serumlevels of CA50,CA 199,CA 125,neurons pecificenol as and CEA in lung cancer benign disease of lung[J].Biomedicine and Pharmacotherapy,1989,(08):613-620.
6Zaleska J,Pirozynski M,Kwiek S. CEA,NSE and SCCAG in biociall avage in patients with lung cancer[J].Rocz Akad Medialymst,1997,(suppl 1):179-183.
7Bach P B. Smoking as a factor in causing lung cancer[J]. JA- MA, 2009, 301(5): 539-541.
8Sallah S, Wan J Y, Nguyen. N P. Venous thrombosis in pa- tients with solid tumors : determination of frequency and charac- teristics[J]. ThrombHaemost, 2002, 87(4): 576-579.
